Search clinical trials for: Crisaborole 2%

Total 16064 results

Pfizer

Terminated

A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

Japan
Pfizer

Completed

A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis

Atopic Dermatitis

China, United States, Turkey, Australia, Canada, Israel
Pfizer

Completed

A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States, Australia, Canada
Pfizer

Completed

A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis

Healthy | Atopic Dermatitis

Japan
Pfizer

Completed

Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥2 Years With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

Japan
Innovaderm Research Inc.

Completed

Different Application Rates of Crisaborole Ointment 2% in Adults With Mild to Moderate Atopic Dermatitis

Dermatitis, Atopic

Canada
University of California, Irvine
Pfizer

Completed

Characterizing Skin Microbiome Change in Atopic Dermatitis

Atopic Dermatitis | Atopic Dermatitis Eczema

United States
Pfizer

Completed

Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

China, Japan, Korea, Republic of
Massachusetts General Hospital
Pfizer

Active, not recruiting

Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States
Pfizer

Completed

Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis

Dermatitis, Atopic

Canada
Northwestern University
Pfizer

Completed

Wearable Skin Sensors to Assess Nocturnal Scratch Behavior

Atopic Dermatitis

United States
Boston University
Pfizer

Terminated

Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis (PAD)

Atopic Dermatitis

United States
Pfizer

Completed

Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis

Stasis Dermatitis

United States
Duke University
Pfizer

Completed

Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea

Morphea

United States
Tufts Medical Center
Pfizer

Withdrawn

Topical Crisaborole in Patients With Alopecia Areata

Alopecia Areata

United States
Ann & Robert H Lurie Children's Hospital of Chicago
Pfizer

Completed

Response of Children With Atopic Dermatitis (Eczema) to Eucrisa

Eczema | Atopic Dermatitis

United States
University of Alabama at Birmingham

Completed

A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis

Seborrheic Dermatitis

United States
University of Colorado, Denver
Pfizer

Active, not recruiting

Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo

Vitiligo

United States
Sun Yat-sen University

Recruiting

Crisaborole Ointment for Skin Toxicity Induced by Cetuximab (COSTIC)

Metastatic Colorectal Cancer | Cetuximab | Skin Toxicity

China
Pfizer

Terminated

A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD

Atopic Dermatitis

United States, Poland, Germany, United Kingdom, Italy, Sweden, Switzerland
University of Rochester

Completed

ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis

Atopic Dermatitis

United States
Clinical Research Center of the Carolinas
Pfizer

Completed

Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period

Atopic Dermatitis

United States
Sheffield Teaching Hospitals NHS Foundation Trust
University of Sheffield

Completed

Skin bioMARkers for Atopic Eczema Therapy Evaluation (SMART)

Atopic Eczema/Dermatitis (Non-Specific)

United Kingdom
Johns Hopkins University
Pfizer

Active, not recruiting

Steroid-reducing Effects of Crisaborole

Eczema | Atopic Dermatitis

United States
Galderma R&D

Completed

Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines (READY-4)

Lateral Canthal Lines | Glabellar Lines

United States, Puerto Rico
University College, London
Moorfields Eye Hospital NHS Foundation Trust; Targeted Genetics Corporation

Completed

Safety Study of RPE65 Gene Therapy to Treat Leber Congenital Amaurosis

Retinal Degeneration

United Kingdom
Merck Sharp & Dohme LLC

Completed

A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295)

HIV Infections
Yuhan Corporation

Completed

Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of YHB1411-2 in Healthy Male Volunteers

Rheumatic Arthritis

Korea, Republic of
Medifast, Inc.

Completed

Retrospective Chart Review of the 5 & 2 & 2 and 4 & 2 & 1 Plans

Obesity

United States
University of South Carolina

Terminated

NEAT!2 Sedentary Behavior Reduction for Individuals With Past or Present Knee Symptoms, Injuries, or Surgeries

Sedentary Lifestyle | Knee Osteoarthritis | Knee Injuries | Knee Pain Chronic

United States
University of Pennsylvania
National Cancer Institute (NCI); Pfizer

Completed

Nicotinic Receptor Levels After Stopping Smoking

Nicotine Addiction

United States
Metabolic Technologies Inc.
National Institute on Aging (NIA); Vanderbilt University

Completed

2-HOBA: Initial Evaluation in Humans (2-HOBA)

Healthy Volunteers

United States
University of Sao Paulo General Hospital

Completed

Comparison of Posterior Tibial Nerve Electrical Stimulation Protocols for Overactive Bladder Syndrome

Overactive Bladder Syndrome

Brazil
Metabolic Technologies Inc.
National Institute on Aging (NIA); Vanderbilt University

Completed

Brain Penetrance of 2-HOBA in Humans (2-HOBA)

Healthy Adults

United States
Hanmi Pharmaceutical Company Limited

Completed

A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients

Hypertension

Korea, Republic of
Sanofi Pasteur, a Sanofi Company
Immune Design

Terminated

Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2 (HSV15)

Genital Herpes

United States
Vanderbilt University Medical Center
American Heart Association

Active, not recruiting

2-Hydroxybenzylamine (2-HOBA) to Prevent Early Recurrence of Atrial Fibrillation After Catheter-based Ablation

Atrial Fibrillation

United States
Children's Hospital Medical Center, Cincinnati
Nationwide Children's Hospital; University of Cincinnati; Connecticut Children... and other collaborators

Recruiting

Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy (PRIME)

Inflammatory Bowel Diseases | Crohn Disease | Ulcerative Colitis

United States
Vanderbilt University Medical Center
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)

Familial Hypercholesterolemia

United States
Metabolic Technologies Inc.
National Institute on Aging (NIA); Vanderbilt University

Completed

2-HOBA: Multiple Dosing Study in Older Adults (2-HOBA)

Older Adults

United States
Metabolic Technologies Inc.
National Institute on Aging (NIA); Vanderbilt University

Completed

2-HOBA: Multiple Dosing Study in Healthy Humans (2-HOBA)

Healthy Volunteers

United States
Coloplast A/S

Completed

Comparison of Two Urostomy Bags (2-piece).

Urostomy Patent

Germany
Baiya Phytopharm Co., Ltd.
National Vaccine Institute, Thailand

Active, not recruiting

Evaluation of the Safety, Tolerability, and Reactogenicity of the Baiya SARS-CoV-2 Vax 2 Vaccine for COVID-19 Disease

COVID-19 Vaccine

Thailand
Université de Montréal

Completed

Peri-Implant Healing Around Two Different Machined-Collar Designs After 25 Years of Function

Jaw, Edentulous

Canada
National Institute of Arthritis and Musculoskeletal...

Completed

Positron Emission Tomography (PET) to Locate Areas of White Blood Cell Activity

Lupus Erythematosus | Systemic

United States
Ajou University School of Medicine

Completed

Fentanyl Background Infusion for Acute Postoperative Pain

Analgesia Disorder

Korea, Republic of
Columbia University
National Institute on Drug Abuse (NIDA); Medical University of South Carolina; University of Pittsburgh and other collaborators

Completed

HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S. (Aware)

HIV/AIDS | Sexually Transmitted Infections

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

Safety and Pharmacokinetic Study of C13-URA in Healthy Volunteers

Gastroparesis

United States
Bausch & Lomb Incorporated

Completed

Study to Explore the Pharmacokinetics and Pharmacodynamics of Epinephrine in Healthy Male and Female Subjects With Different Skin to Muscle Depth (STMD)

Anaphylaxis

Germany
AGIR à Dom

Completed

Continuous Positive Airway Pressure (CPAP) Mode Impact on Clinical Blood Arterial Pressure (AgirSASadom)

Obstructive Sleep Apnea Syndrome

France

Search clinical trials for: Crisaborole 2%

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations